Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 22.4% – Should You Buy?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price traded up 22.4% during mid-day trading on Wednesday . The company traded as high as $4.46 and last traded at $4.5540. 404,040 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 565,461 shares. The stock had previously closed at $3.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Indaptus Therapeutics presently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Performance

The company has a market cap of $521.02 million, a P/E ratio of -0.30 and a beta of 1.25. The stock’s fifty day moving average price is $2.35 and its two-hundred day moving average price is $2.26.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($1.87) by $1.64.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.